Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill
OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.